Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 384

1.

Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options.

Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranel J, Blons H, Goldwasser F, Laurent-Puig P.

J Med Genet. 2018 Oct 23. pii: jmedgenet-2018-105594. doi: 10.1136/jmedgenet-2018-105594. [Epub ahead of print]

PMID:
30352869
2.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. French.

PMID:
30343945
3.

Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: a gene-set analysis.

Berrandou T, Mulot C, Cordina-Duverger E, Arveux P, Laurent-Puig P, Truong T, Guénel P.

Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31917. [Epub ahead of print]

PMID:
30303517
4.

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J, Franchimont D, Verset L, Galdon MG, Devière J, de Reyniès A, Laurent-Puig P, Van Laethem JL, Bachet JB, Maréchal R.

Gastroenterology. 2018 Aug 27. pii: S0016-5085(18)34919-9. doi: 10.1053/j.gastro.2018.08.033. [Epub ahead of print]

PMID:
30165049
5.

Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights.

Cohen R, Sroussi M, Pilati C, Houry S, Laurent-Puig P, André T.

J Gastrointest Oncol. 2018 Aug;9(4):E23-E27. doi: 10.21037/jgo.2018.05.10.

6.

Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity.

Uchuya-Castillo J, Aznar N, Frau C, Martinez P, Le Nevé C, Marisa L, Penalva LOF, Laurent-Puig P, Puisieux A, Scoazec JY, Samarut J, Ansieau S, Plateroti M.

Oncotarget. 2018 Jul 24;9(57):30979-30996. doi: 10.18632/oncotarget.25741. eCollection 2018 Jul 24.

7.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
8.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

9.

Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.

Laurent-Puig P, Grisoni ML, Heinemann V, Liebaert F, Neureiter D, Jung A, Montestruc F, Gaston-Mathe Y, Thiébaut R, Stintzing S.

Clin Cancer Res. 2018 Aug 14. pii: clincanres.1324.2018. doi: 10.1158/1078-0432.CCR-18-1324. [Epub ahead of print]

PMID:
30108104
10.

Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' reply.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 Sep;50(9):974-975. doi: 10.1016/j.dld.2018.06.014. Epub 2018 Jun 28. No abstract available.

PMID:
30005959
11.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

PMID:
29921730
12.

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

Garinet S, Laurent-Puig P, Blons H, Oudart JB.

J Clin Med. 2018 Jun 9;7(6). pii: E144. doi: 10.3390/jcm7060144. Review.

13.

Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation.

Leclerc J, Flament C, Lovecchio T, Delattre L, Ait Yahya E, Baert-Desurmont S, Burnichon N, Bronner M, Cabaret O, Lejeune S, Guimbaud R, Morin G, Mauillon J, Jonveaux P, Laurent-Puig P, Frébourg T, Porchet N, Buisine MP.

Genet Med. 2018 Apr 12. doi: 10.1038/gim.2018.47. [Epub ahead of print]

PMID:
29790873
14.

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples.

Legras A, Barritault M, Tallet A, Fabre E, Guyard A, Rance B, Digan W, Pecuchet N, Giroux-Leprieur E, Julie C, Jouveshomme S, Duchatelle V, Giraudet V, Gibault L, Cazier A, Pastre J, Le Pimpec-Barthes F, Laurent-Puig P, Blons H.

J Mol Diagn. 2018 Jul;20(4):550-564. doi: 10.1016/j.jmoldx.2018.04.002. Epub 2018 May 19.

PMID:
29787863
15.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 May 15. doi: 10.1158/1078-0432.CCR-18-0163. [Epub ahead of print]

PMID:
29764856
16.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

Moati E, Taly V, Didelot A, Perkins G, Blons H, Taieb J, Laurent-Puig P, Zaanan A.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):396-402. doi: 10.1016/j.clinre.2018.03.002. Epub 2018 Apr 5.

PMID:
29627453
17.

Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients.

Boeckx N, Op de Beeck K, Beyens M, Deschoolmeester V, Hermans C, De Clercq P, Garrigou S, Normand C, Monsaert E, Papadimitriou K, Laurent-Puig P, Pauwels P, Van Camp G, Taly V, Peeters M.

Clin Colorectal Cancer. 2018 Jun;17(2):e369-e379. doi: 10.1016/j.clcc.2018.02.006. Epub 2018 Feb 22.

PMID:
29605591
18.

Oesophago-gastric cancer: One disease or separate entities?: Translating molecular subtyping into clinical practice.

Laurent-Puig P.

Eur J Cancer. 2018 Mar;92 Suppl 2:S1. doi: 10.1016/j.ejca.2018.01.090. No abstract available.

PMID:
29553384
19.

BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA.

Andriamanampisoa CL, Bancaud A, Boutonnet-Rodat A, Didelot A, Fabre J, Fina F, Garlan F, Garrigou S, Gaudy C, Ginot F, Henaff D, Laurent-Puig P, Morin A, Picot V, Saias L, Taly V, Tomasini P, Zaanan A.

Anal Chem. 2018 Mar 20;90(6):3766-3774. doi: 10.1021/acs.analchem.7b04034. Epub 2018 Mar 9.

PMID:
29498256
20.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.

Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.

PMID:
29438522
21.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C.

Dig Liver Dis. 2018 Apr;50(4):408-410. doi: 10.1016/j.dld.2018.01.119. Epub 2018 Mar 1.

PMID:
29409778
22.

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza RA, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 May;50(5):507-512. doi: 10.1016/j.dld.2017.12.029. Epub 2018 Jan 8.

23.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2018 Jan 23;15(3):150. doi: 10.1038/nrclinonc.2018.13. [Epub ahead of print]

PMID:
29358775
24.

Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.

Pugh S, Thiébaut R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, Laurent-Puig P.

Oncotarget. 2017 Sep 27;8(55):93856-93866. doi: 10.18632/oncotarget.21291. eCollection 2017 Nov 7.

25.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators.

JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12.

PMID:
29167892
26.

Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.

Postel M, Roosen A, Laurent-Puig P, Taly V, Wang-Renault SF.

Expert Rev Mol Diagn. 2018 Jan;18(1):7-17. doi: 10.1080/14737159.2018.1400384. Epub 2017 Nov 13.

PMID:
29115895
27.

Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.

Legras A, Roussel H, Mangiameli G, Arame A, Grand B, Pricopi C, Badia A, Gibault L, Badoual C, Fabre E, Laurent-Puig P, Blons H, Le Pimpec-Barthes F.

Pathol Oncol Res. 2017 Nov 6. doi: 10.1007/s12253-017-0352-x. [Epub ahead of print]

PMID:
29110262
28.

[Lynch syndrome and endometrial cancer].

Bats AS, Rossi L, Le Frere-Belda MA, Narjoz C, Cournou C, Gosset M, Ngo C, Delomenie M, Nos C, Blons H, Laurent-Puig P, Lecuru F.

Bull Cancer. 2017 Dec;104(12):1013-1021. doi: 10.1016/j.bulcan.2017.06.018. Epub 2017 Oct 21. Review. French.

PMID:
29061399
29.

An architecture for genomics analysis in a clinical setting using Galaxy and Docker.

Digan W, Countouris H, Barritault M, Baudoin D, Laurent-Puig P, Blons H, Burgun A, Rance B.

Gigascience. 2017 Nov 1;6(11):1-9. doi: 10.1093/gigascience/gix099.

30.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.

Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.

JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899.

31.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx136.

PMID:
28922790
32.

A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Petitgas C, Ceballos-Picot I, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Sci Rep. 2017 Sep 5;7(1):10550. doi: 10.1038/s41598-017-10338-6.

33.

Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.

Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P, Blons H.

Cancers (Basel). 2017 Aug 3;9(8). pii: E101. doi: 10.3390/cancers9080101. Review.

34.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

PMID:
28651158
35.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).

Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, Taieb J, Di Fiore F, Taly V, Zaanan A.

Clin Cancer Res. 2017 Sep 15;23(18):5416-5425. doi: 10.1158/1078-0432.CCR-16-3155. Epub 2017 Jun 2.

36.

6-mercaptopurine promotes energetic failure in proliferating T cells.

Fernández-Ramos AA, Marchetti-Laurent C, Poindessous V, Antonio S, Laurent-Puig P, Bortoli S, Loriot MA, Pallet N.

Oncotarget. 2017 Jun 27;8(26):43048-43060. doi: 10.18632/oncotarget.17889.

37.

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Garlan F, Blanchet B, Kramkimel N, Puszkiel A, Golmard JL, Noe G, Dupin N, Laurent-Puig P, Vidal M, Taly V, Thomas-Schoemann A.

Target Oncol. 2017 Jun;12(3):365-371. doi: 10.1007/s11523-017-0491-8.

PMID:
28527094
38.

Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study.

Rossi L, Le Frere-Belda MA, Laurent-Puig P, Buecher B, De Pauw A, Stoppa-Lyonnet D, Canlorbe G, Caron O, Borghese B, Colas C, Delhomelle H, Chabbert-Buffet N, Grandjouan S, Lecuru F, Bats AS.

Int J Gynecol Cancer. 2017 Jun;27(5):953-960. doi: 10.1097/IGC.0000000000000985.

PMID:
28525912
39.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

40.

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.

Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F.

Eur J Cancer. 2017 Jul;79:41-49. doi: 10.1016/j.ejca.2017.03.022. Epub 2017 Apr 29.

41.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

Auclin E, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.

Ann Oncol. 2017 May 1;28(5):958-968. doi: 10.1093/annonc/mdx030. Review.

PMID:
28453690
42.

Erratum to: Partnering with patients in translational oncology research: ethical approach.

Mamzer MF, Duchange N, Darquy S, Marvanne P, Rambaud C, Marsico G, Cerisey C, Scotté F, Burgun A, Badoual C, Laurent-Puig P, Hervé C.

J Transl Med. 2017 Apr 23;15(1):80. doi: 10.1186/s12967-017-1181-0. No abstract available.

43.

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities.

Pécuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M.

Ann Oncol. 2017 Jul 1;28(7):1597-1604. doi: 10.1093/annonc/mdx162.

PMID:
28419182
44.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.

Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group.

BMC Public Health. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

45.

Partnering with patients in translational oncology research: ethical approach.

Mamzer MF, Duchange N, Darquy S, Marvanne P, Rambaud C, Marsico G, Cerisey C, Scotté F, Burgun A, Badoual C, Laurent-Puig P, Hervé C.

J Transl Med. 2017 Apr 8;15(1):74. doi: 10.1186/s12967-017-1177-9. Erratum in: J Transl Med. 2017 Apr 23;15(1):80.

46.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2017 Sep;14(9):562-576. doi: 10.1038/nrclinonc.2017.40. Epub 2017 Apr 4. Review. Erratum in: Nat Rev Clin Oncol. 2018 Jan 23;:.

PMID:
28374784
47.

CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.

Pilati C, Taieb J, Balogoun R, Marisa L, de Reyniès A, Laurent-Puig P.

Ann Oncol. 2017 May 1;28(5):1032-1035. doi: 10.1093/annonc/mdx066.

PMID:
28328000
48.

Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine.

Stoeklé HC, Mamzer-Bruneel MF, Frouart CH, Le Tourneau C, Laurent-Puig P, Vogt G, Hervé C.

Sci Eng Ethics. 2018 Feb;24(1):307-322. doi: 10.1007/s11948-017-9880-8. Epub 2017 Mar 9.

49.

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.

Pilati C, Shinde J, Alexandrov LB, Assié G, André T, Hélias-Rodzewicz Z, Ducoudray R, Le Corre D, Zucman-Rossi J, Emile JF, Bertherat J, Letouzé E, Laurent-Puig P.

J Pathol. 2017 May;242(1):10-15. doi: 10.1002/path.4880. Epub 2017 Mar 29.

PMID:
28127763
50.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw272. Print 2017 May.

Supplemental Content

Loading ...
Support Center